VRTX Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 37.71% compared to Vertex Pharmaceuticals's net margin of 16.61%. Vertex Pharmaceuticals's return on equity of -2.89% beat Gilead Sciences's return on equity of 0.64%.

Vertex Pharmaceuticals has a consensus price target of $498.37, signalling upside risk potential of 25.42%. On the other hand Gilead Sciences has an analysts' consensus of $98.92 which suggests that it could grow by 6.86%. Given that Vertex Pharmaceuticals has higher upside potential than Gilead Sciences, analysts believe Vertex Pharmaceuticals is more attractive than Gilead Sciences.

Vertex Pharmaceuticals has a beta of 0.364, which suggesting that the stock is 63.631% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.175, suggesting its less volatile than the S&P 500 by 82.499%.

Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 3.33% to investors and pays a quarterly dividend of $0.77 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. Gilead Sciences pays out 67.24% of its earnings as a dividend. Gilead Sciences's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vertex Pharmaceuticals quarterly revenues are $2.8B, which are smaller than Gilead Sciences quarterly revenues of $7.5B. Vertex Pharmaceuticals's net income of $1B is lower than Gilead Sciences's net income of $1.3B. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 25.59x while Gilead Sciences's PE ratio is 1,028.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 9.73x versus 4.09x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 37.71% compared to Vertex Pharmaceuticals's net margin of 8.48%. Vertex Pharmaceuticals's return on equity of -2.89% beat Eli Lilly and's return on equity of 66.4%.

Vertex Pharmaceuticals has a consensus price target of $498.37, signalling upside risk potential of 25.42%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 28.17%. Given that Eli Lilly and has higher upside potential than Vertex Pharmaceuticals, analysts believe Eli Lilly and is more attractive than Vertex Pharmaceuticals.

Vertex Pharmaceuticals has a beta of 0.364, which suggesting that the stock is 63.631% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.68% to investors and pays a quarterly dividend of $1.30 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vertex Pharmaceuticals quarterly revenues are $2.8B, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Vertex Pharmaceuticals's net income of $1B is higher than Eli Lilly and's net income of $970.3M. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 25.59x while Eli Lilly and's PE ratio is 83.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 9.73x versus 16.99x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 37.71% compared to Vertex Pharmaceuticals's net margin of 25.23%. Vertex Pharmaceuticals's return on equity of -2.89% beat Pfizer's return on equity of 4.63%.

Vertex Pharmaceuticals has a consensus price target of $498.37, signalling upside risk potential of 25.42%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 20.88%. Given that Vertex Pharmaceuticals has higher upside potential than Pfizer, analysts believe Vertex Pharmaceuticals is more attractive than Pfizer.

Vertex Pharmaceuticals has a beta of 0.364, which suggesting that the stock is 63.631% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.37% to investors and pays a quarterly dividend of $0.42 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Vertex Pharmaceuticals quarterly revenues are $2.8B, which are smaller than Pfizer quarterly revenues of $17.7B. Vertex Pharmaceuticals's net income of $1B is lower than Pfizer's net income of $4.5B. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 25.59x while Pfizer's PE ratio is 35.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 9.73x versus 2.52x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

PTC Therapeutics has a net margin of 37.71% compared to Vertex Pharmaceuticals's net margin of -54.2%. Vertex Pharmaceuticals's return on equity of -2.89% beat PTC Therapeutics's return on equity of --.

Vertex Pharmaceuticals has a consensus price target of $498.37, signalling upside risk potential of 25.42%. On the other hand PTC Therapeutics has an analysts' consensus of -- which suggests that it could grow by 26.98%. Given that PTC Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe PTC Therapeutics is more attractive than Vertex Pharmaceuticals.

Vertex Pharmaceuticals has a beta of 0.364, which suggesting that the stock is 63.631% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.629, suggesting its less volatile than the S&P 500 by 37.101%.

Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.

Vertex Pharmaceuticals quarterly revenues are $2.8B, which are larger than PTC Therapeutics quarterly revenues of $196.8M. Vertex Pharmaceuticals's net income of $1B is higher than PTC Therapeutics's net income of -$106.7M. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 25.59x while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 9.73x versus 3.92x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.